Search results
Results From The WOW.Com Content Network
The Hedgehog signaling pathway is a signaling pathway that transmits information to embryonic cells required for proper cell differentiation. Different parts of the embryo have different concentrations of hedgehog signaling proteins. The pathway also has roles in the adult. Diseases associated with the malfunction of this pathway include cancer ...
Thus, Hedgehog pathway inhibitors are an important class of anti-cancer drugs. [10] [11] [12] At least three Hedgehog pathway inhibitors have been approved by the Food and Drug Administration (FDA) for cancer treatment. [12]
Sonidegib , sold under the brand name Odomzo, is a medication used to treat cancer. [ 1 ] Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism).
It also is the target of vismodegib, the first hedgehog pathway inhibitor to be approved by the U.S. Food and Drug Administration (FDA). [8] Smoothened (Smo) is a key transmembrane protein that is a key component of the hedgehog signaling pathway, a cell-cell communication system critical for embryonic development and adult tissue homeostasis.
The sonic hedgehog transcription pathway has also been linked to the formation of specific kinds of cancerous tumors, including the embryonic cerebellar tumor [30] and medulloblastoma, [31] as well as the progression of prostate cancer tumours. [32]
Beachy also pioneered small molecule Hedgehog pathway inhibitors, leading to FDA approval of three such inhibitors (vismodegib, sonidegib, and glasdegib) for the treatment of basal cell carcinoma and chronic myelogenous leukemia. 1. Hedgehog protein identification. Hedgehog signaling was unknown when Beachy began his work in the early 1990s.
Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma. [1]
Vismodegib, sold under the brand name Erivedge, is a medication used for the treatment of basal-cell carcinoma (BCC). [3] The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. [4]